BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1231 related articles for article (PubMed ID: 23333535)

  • 1. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topotecan vitreous and plasma levels and retinal toxicity after transcorneal intravitreal delivery in healthy albino rabbits: alternative retinoblastoma treatment.
    Darsova D; Pochop P; Uhlik J; Klapkova E; Tesfaye H; Kodetova D; Lestak J; Malis J; Vajner L
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Dec; 156(4):318-23. PubMed ID: 22660213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
    Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
    Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: Implications for retinoblastoma treatment.
    Del Sole MJ; Clausse M; Nejamkin P; Cancela B; Del Río M; Lamas G; Lubieniecki F; Francis JH; Abramson DH; Chantada G; Schaiquevich P
    Exp Eye Res; 2022 May; 218():109026. PubMed ID: 35276184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment.
    Buitrago E; Höcht C; Chantada G; Fandiño A; Navo E; Abramson DH; Schaiquevich P; Bramuglia GF
    Exp Eye Res; 2010 Jul; 91(1):9-14. PubMed ID: 20307538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.
    Carcaboso AM; Bramuglia GF; Chantada GL; Fandiño AC; Chiappetta DA; de Davila MT; Rubio MC; Abramson DH
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3761-7. PubMed ID: 17652749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is intravitreal topotecan toxic to retinal function?
    Nadelmann J; Francis JH; Brodie SE; Muca E; Abramson DH
    Br J Ophthalmol; 2021 Jul; 105(7):1016-1018. PubMed ID: 32665221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.
    Bogan CM; Pierce JM; Doss SD; Tao YK; Chen SC; Boyd KL; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
    Exp Eye Res; 2021 Mar; 204():108439. PubMed ID: 33444583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma.
    Winter U; Buitrago E; Mena HA; Del Sole MJ; Laurent V; Negrotto S; Francis J; Arana E; Sgroi M; Croxatto JO; Djaballah H; Chantada GL; Abramson D; Schaiquevich P
    Invest Ophthalmol Vis Sci; 2015 Jul; 56(8):4382-93. PubMed ID: 26176875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
    Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
    Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
    Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R
    JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
    Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.
    Francis JH; Brodie SE; Marr B; Zabor EC; Mondesire-Crump I; Abramson DH
    Ophthalmology; 2017 Apr; 124(4):488-495. PubMed ID: 28089679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma.
    Rao R; Honavar SG; Sharma V; Reddy VAP
    Br J Ophthalmol; 2018 Apr; 102(4):490-495. PubMed ID: 28844050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular pharmacology of topotecan and its activity in retinoblastoma.
    Schaiquevich P; Carcaboso AM; Buitrago E; Taich P; Opezzo J; Bramuglia G; Chantada GL
    Retina; 2014 Sep; 34(9):1719-27. PubMed ID: 25099219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model.
    Lee JE; Lim DW; Park HJ; Shin JH; Lee SM; Oum BS
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):2924-9. PubMed ID: 21228384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture.
    Shields CL; Douglass AM; Beggache M; Say EA; Shields JA
    Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.
    Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M
    Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier.
    Pascual-Pasto G; Olaciregui NG; Opezzo JAW; Castillo-Ecija H; Cuadrado-Vilanova M; Paco S; Rivero EM; Vila-Ubach M; Restrepo-Perdomo CA; Torrebadell M; Suñol M; Schaiquevich P; Mora J; Bramuglia GF; Chantada GL; Carcaboso AM
    J Control Release; 2017 Oct; 264():34-44. PubMed ID: 28830790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.
    Chao A; Kao LY; Liu L; Wang NK
    BMC Ophthalmol; 2016 Mar; 16():27. PubMed ID: 26975871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.